{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031425","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.826581+00:00","generated_at":"2026-06-08T05:13:58.310958+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pulse Biosciences Q3 net loss $10.6M; advances cardiac ablation devices toward 510(k) and first-in-human","bullets":["GAAP net loss of $10.6M for Q3 2023 vs $18.0M in Q3 2022; non-GAAP net loss $8.5M vs $16.8M.","Cash and cash equivalents $50.4M as of Sept 30, 2023 vs $69.2M a year ago; Q3 cash burn $8.7M.","Plan to file 510(k) for cardiac ablation surgical clamp and initiate first-in-human catheter procedure between Dec 2023 and Q1 2024.","Appointed Dr. Niv Ad as Chief Science Officer, Cardiac Surgery to lead clinical strategy.","Completed treatment of 21 subjects in thyroid clinical feasibility study; started additional group Nov 7, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031425","json":"https://secwatch.observer/filing/0001437749-23-031425.json","markdown":"https://secwatch.observer/filing/0001437749-23-031425.md","text":"https://secwatch.observer/filing/0001437749-23-031425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923031425/0001437749-23-031425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923031425/plse20231108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:13:58.310958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"96d9603f8ead976b3ee3d051749744d00216e473","claim":"PULSE BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income ($10.6) million.","evidence_excerpt":"GAAP net loss for the three months ended September 30, 2023 was ($10.6) million compared to ($18.0) million for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923031425/0001437749-23-031425-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"($10.6) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}